Overview
Ambio Life Sciences is an organization dedicated to delivering ibogaine-based treatments, emphasizing the management of addictions and mental health disorders including trauma, traumatic brain injury (TBI), chronic pain, and other neurological conditions. The company operates clinics in Gabon and Mexico, asserting plans to scale from treating four patients per week to forty, although these claims require verification [1]. Its mission combines medically supervised treatment, psychotherapy, and traditional cultural practice in an integrative approach [2].
History
Ambio Life Sciences was co-founded by Jonathan Dickinson, Trevor Millar, and José Inzunza with its establishment recorded in 2021. Dickinson has been involved in clinical ibogaine work since 2009, additionally authoring the 'Clinical Guidelines for Ibogaine-Assisted Detoxification' [1]. The organization's trajectory reflects an effort to merge Western clinical practices with traditional Gabonese knowledge surrounding ibogaine utilization [2].
The specific details of Ambio’s founding activities, including financing and corporate history, remain inadequately documented in publicly available sources, suggesting a need for more comprehensive corporate transparency [1].
Leadership
Jonathan Dickinson serves as the CEO and co-founder of Ambio Life Sciences, presenting himself as a licensed psychologist in Mexico and previously acting as the executive director of the Global Ibogaine Therapy Alliance. He has notably claimed that ibogaine can 'restore cognitive choices' and is involved in addressing blast-related brain injuries. Dickinson's credentials, including his psychology license and clinical qualifications, require further independent verification [1].
Dr. Millar holds the position of Chief Operating Officer and Dr. Inzunza is the Chief Medical Officer, yet publicly available information does not clarify their clinical responsibilities or licenses.
Additionally, Dickinson authored the book titled *Ibogaine and the Bicameral Mind: The Definitive Clinical and Cultural Guide to Ibogaine*, released on September 8, 2026, further solidifying his influence in the field [2].
Programs and Pipeline
Ambio Life Sciences promotes a range of treatments based on medically supervised ibogaine therapy aimed at various neurological and psychological conditions. Their operational model primarily appears to rely on fee-for-service residential treatment rather than being a traditional pharmaceutical development company. Ambio has plans to expand clinical services significantly while integrating traditional practices, particularly those from Gabon [1].
The organization has referenced combined treatment protocols that may also involve substances such as 5-MeO-DMT alongside ibogaine [2].
Although Ambio claims an association with a Stanford Nature Medicine paper reporting an '88% reduction' in PTSD symptoms, the existence, methodology, and specifics of this research remain unverified and should not be treated as established clinical findings at this time.[3]
Partnerships and Supply
Ambio Life Sciences asserts having the only active export license for *Tabernanthe iboga*, permitting them to operate their sourcing from Gabon, yet no detailed evidence regarding the licensing process, including issuing authority or license validity, has been provided. The company claims to integrate Gabonese traditional practices into its operations but lacks documented formal partnerships with local communities or Gabonese officials [2].
Verification of Ambio's supply chain, including contracts with pharmaceutical manufacturers or independent testing laboratories, remains unclear within available sources [1].
Regulatory and Clinical Activity
The company’s operations must comply with local regulations regarding health services in Mexico and Gabon, yet confirmation of appropriate licenses or permits is still pending [1]. In April 2026, a significant executive order (Executive Order 14401) was issued in the United States, aiming to improve access to medical treatments for serious mental illnesses. The executive order directs federal agencies to facilitate potential access to psychedelic therapies including ibogaine.
Despite Ambio's claims, comprehensive documentation such as institutional review board (IRB) approvals, clinical trial registrations, or reported adverse events have not been thoroughly reviewed, indicating a need for careful scrutiny in the future [1].